Drug Type Small molecule drug |
Synonyms SSR 241586, SSR241586 |
Target |
Action antagonists |
Mechanism NK2R antagonists(Neurokinin 2 receptor antagonists), NK3 antagonists(Neurokinin 3 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H42Cl2N4O3 |
InChIKeyRVQZVVJLIUXDPN-YTTGMZPUSA-N |
CAS Registry1239279-30-1 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anxiety Disorders | Phase 1 | France | - | |
| Anxiety Disorders | Phase 1 | - | - | |
| Depressive Disorder, Major | Phase 1 | France | - | |
| Depressive Disorder, Major | Phase 1 | - | - | |
| Irritable Bowel Syndrome | Phase 1 | France | - | |
| Irritable Bowel Syndrome | Phase 1 | - | - | |
| Schizophrenia | Phase 1 | France | - | |
| Schizophrenia | Phase 1 | - | - |





